---
id: competitor-cardiotrace-inc
title: "CardioTrace Inc"
type: competitor
namespace: competitive
summary: "Direct fictional competitor in adult ambulatory cardiac telemetry; two 510(k) clearances with expanding IFU history; competes head-on with Vitalisens."
auto_inject: false
applicable_when: null
confidence: 0.85
verified_at: 2026-05-21
verified_by: nemock
staleness_signal: "Refresh after any new CardioTrace 510(k), press release, or material website change."
tags: [competitor, direct]
legal_name: "CardioTrace Inc"
canonical_url: "https://cardiotrace-inc.example.com"
edges:
  - target: indication-for-use-cardiotrace-pro-2023-q1
    type: related_to
    weight: 0.9
    note: "Initial cleared IFU."
  - target: indication-for-use-cardiotrace-pro-2025-q3
    type: related_to
    weight: 0.9
    note: "Expanded IFU after their second clearance."
  - target: regulatory-clearance-K181234-cardiotrace-pro-v1
    type: related_to
    weight: 0.9
    note: "First 510(k) clearance."
  - target: regulatory-clearance-K231234-cardiotrace-pro-v2
    type: related_to
    weight: 0.9
    note: "Second 510(k) clearance, expanded IFU."
  - target: source-press-release-cardiotrace-2025-q3-launch
    type: related_to
    weight: 0.7
    note: "Announcement of the v2 clearance and expanded IFU."
  - target: source-web-snapshot-cardiotrace-product-page-2026-05-20
    type: related_to
    weight: 0.8
    note: "Current product page snapshot."
  - target: source-fda-510k-summary-K231234-cardiotrace
    type: related_to
    weight: 0.9
    note: "Public clearance summary for the K231234 filing."
related: []
source_url: null
controlled_document: false
---

# CardioTrace Inc

## Summary

A fictional direct competitor in adult ambulatory cardiac telemetry. Two cleared products (one wearable, two clearance generations). Most-monitored competitor in this vault.

## Content

Positioning: "Continuous cardiac monitoring you can wear for 14 days." CardioTrace markets a single 14-day pad as their differentiator vs. legacy Holter monitors.

Strengths (per public signals):

- 14-day wear claim.
- Established reimbursement coding alignment.
- Two generations of cleared product → predicate-strength for their next filing.

Weaknesses (per our hypothesis):

- Pad failure rates beyond day 10 (per our trial data; not confirmable from public CardioTrace data).
- Clinician app reportedly behind on EHR integration depth (per the customer-interview source).
- IFU expansion in 2025 added clinical claims that may exceed validated performance.

## Edges

Many `related_to` edges because this competitor anchors a substantial sub-graph: two IFU versions, two clearances, one web snapshot, one press release, one FDA summary. The vault would feel sparse without these connections.

## Notes

`legal_name` and `canonical_url` are populated per schema requirements for competitor nodes. The canonical URL is fictional (`example.com` domain) to avoid pointing at a real company.

Next monitoring action: re-snapshot product page in 6 months; check for a 30-day claim emerging.
